Literature DB >> 7691455

The effects of recombinant human granulocyte colony-stimulating factor on passive collagen-induced arthritis transferred with anti-type II collagen antibody.

H Miyahara1, T Hotokebuchi, I Saikawa, C Arita, K Takagishi, Y Sugioka.   

Abstract

Type II collagen-induced arthritis (CIA) is a pathologic process mediated, in part, by humoral immune mechanisms. Because many antibody-mediated reactions are neutrophil-dependent, the role of this cell population was examined in passive CIA transferred with anti-type II collagen (CII) antibody. In cyclophosphamide (CY)-induced leukocytopenic rats, swelling and inflammation associated with the arthritic response were significantly reduced. Concomitant administration of recombinant human granulocyte colony-stimulating factor (rhG-CSF) to leukocytopenic rats for 7 consecutive days from the day of CY injection resulted in the recovery of peripheral blood neutrophils count and the abrogation of the suppression of arthritis with an optimal dose of anti-CII antibody. Further study demonstrated that a prior administration of rhG-CSF to naive rats for five consecutive days resulted in the significant and specific increase of peripheral blood neutrophils count and enhancement of passive arthritis with a suboptimal dose of anti-CII antibody. It was suggested that neutrophils played an important role in the development of passive CIA.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691455     DOI: 10.1006/clin.1993.1151

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Critical role for granulocyte colony-stimulating factor in inflammatory arthritis.

Authors:  Kate E Lawlor; Ian K Campbell; Donald Metcalf; Kristy O'Donnell; Annemarie van Nieuwenhuijze; Andrew W Roberts; Ian P Wicks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-22       Impact factor: 11.205

Review 2.  Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection.

Authors:  Bao-Guo Xiao; Chuan-Zhen Lu; Hans Link
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.